Epigral Share Price Outlook: Where Could It Be by 2030?

The Epigral share price forecast for the next 3 years is a question on many investors’ minds as the stock trades at Rs 1,052, within a 52 week range of Rs 806 to Rs 2,114. This article lays out a scenario based Epigral share price outlook for 2027, 2028 and 2030, built on the company’s fundamentals, sector trends and the key risks that could change the trajectory. Rather than a single number, the focus here is on the range of outcomes and the assumptions behind each one.

Click Here – Get Free Investment Predictions

Epigral Company Overview

Epigral, formerly Meghmani Finechem, manufactures chlor-alkali and specialty chemicals including chloromethanes and epichlorohydrin for pharma, agrochemical and industrial clients. Understanding the business model is the first step in framing any credible Epigral share price forecast, because the durability of earnings ultimately decides where the stock trades.

Company	Epigral
NSE Ticker	EPIGRAL
CMP	Rs 1,052
52 Week High	Rs 2,114
52 Week Low	Rs 806
Market Cap	Rs 4,540 Cr
Stock PE	13.9
Book Value	Rs 515
ROE	15.8%
ROCE	15.3%
Dividend Yield	0.48%

Where Does Epigral Share Price Stand Today?

The stock currently trades about 50 percent below its 52 week high of Rs 2,114, which means the market has already tempered some of its optimism. For anyone building a Epigral share price forecast, this correction matters for the Epigral share price forecast starting point, because entry valuations have a large bearing on 3 year returns.

At the current price, Epigral commands a market capitalisation of Rs 4,540 Cr and trades at a price to earnings multiple of 13.9. The company generates a return on equity of 15.8% and a return on capital employed of 15.3%, which places it in the category of businesses with moderate return ratios. These numbers anchor the Epigral share price forecast scenarios that follow. How the broader Nifty 50 index trades over this period will also influence the multiple investors are willing to assign to the stock.

Epigral Share Price Forecast: Key Growth Drivers for the Next 3 Years

Four forces are likely to shape the Epigral share price forecast between now and 2030, and together they explain most of the dispersion in this Epigral share price forecast. Each is discussed below with its likely direction of impact.

Earnings Trajectory and Return Ratios

Stock prices ultimately follow earnings. With moderate return ratios at present, the pace at which profits compound over FY27 to FY30 will be the single biggest determinant of the Epigral share price forecast actually playing out. Consistent earnings delivery tends to expand valuation multiples, while misses compress them quickly.

Specialty Chemicals and China Plus One Tailwinds

Global supply chain diversification and domestic demand growth continue to support Indian specialty chemicals. Innovators like Epigral with process chemistry advantages can defend margins better through pricing cycles.

Within the space, investors often benchmark Epigral against peers such as Chemplast Sanmar, DCW and Chemfab Alkalis on growth and valuations before forming a view on the Epigral share price forecast.

Company Specific Catalysts

The bull case for Epigral rests on rising domestic demand for chlor-alkali derivatives and specialty chemicals and capacity expansion. If these play out on schedule, the Epigral share price forecast for 2030 could gravitate toward the upper end of the scenario range discussed below.

Macro Environment and Liquidity

The RBI rate cycle, FII flows into Indian equities and overall market valuations will influence the multiple investors are willing to pay. A benign macro backdrop supports the optimistic end of any Epigral share price forecast, while global risk aversion would do the opposite to the Epigral share price outlook.

Epigral Share Price Forecast 2027, 2028 and 2030: Scenario Analysis

The table below presents a scenario based Epigral share price forecast using compounded annual growth assumptions applied to the current market price of Rs 1,052. These are illustrative ranges, not point predictions, and actual outcomes can fall outside them.

Year	Bear Case	Base Case	Bull Case	Assumption
2027	Rs 1,120	Rs 1,210	Rs 1,310	4% to 16% CAGR on CMP
2028	Rs 1,160	Rs 1,340	Rs 1,530	4% to 16% CAGR on CMP
2030	Rs 1,260	Rs 1,620	Rs 2,050	4% to 16% CAGR on CMP

In the base case scenario of this Epigral share price forecast, the 2030 level works out to roughly Rs 1,620, implying steady compounding from today’s levels. The bull case of Rs 2,050 assumes rising domestic demand for chlor-alkali derivatives and specialty chemicals and capacity expansion delivers ahead of expectations, while the bear case of Rs 1,260 captures a scenario where growth stalls. That is an outcome band of about 20 percent to 95 percent over the period.

Consult a SEBI Registered Investment Advisor Before Acting on Any Forecast

Bull Case vs Bear Case for Epigral Share Price

The Bull Case

The optimistic Epigral share price forecast assumes rising domestic demand for chlor-alkali derivatives and specialty chemicals and capacity expansion. Combined with supportive sector conditions, this could lift both earnings and the valuation multiple, pushing the stock toward Rs 2,050 by 2030.

The Bear Case

The cautious view centres on the fact that energy intensive manufacturing makes margins sensitive to power costs and caustic soda price cycles. If these pressures dominate, the Epigral share price forecast would skew toward the lower band and the stock could stagnate near Rs 1,260 even by 2030, underperforming broader indices.

Key Risks That Could Change the Epigral Share Price Outlook

• Execution risk: Delays in strategy execution or capacity plans would push the earnings trajectory below the base case assumed in this Epigral share price forecast.
• Valuation risk: At a PE of 13.9, any earnings disappointment can trigger sharp multiple compression before fundamentals stabilise.
• Sector risk: Energy intensive manufacturing makes margins sensitive to power costs and caustic soda price cycles.
• Macro risk: A global slowdown, adverse FII flows or unexpected rate moves would compress equity valuations across the market.
• Regulatory risk: Policy, tax or compliance changes affecting the sector can alter the earnings outlook with little warning.

Is Epigral Worth Watching for the Long Term?

For long term investors, the relevant question is not just where the Epigral share price forecast lands in 2030 or what any single Epigral share price forecast says today, but whether the business can compound capital through cycles. The company’s positioning around rising domestic demand for chlor-alkali derivatives and specialty chemicals and capacity expansion gives it a credible growth story, while the risks outlined above define what must be monitored each quarter.

Investors should track quarterly earnings, management commentary and sector data rather than anchoring to any single number from a Epigral share price outlook. Historically, staying focused on business fundamentals has served investors better than chasing price targets, and consulting a SEBI registered advisor before investing remains the prudent approach.

Download the Univest iOS App or Univest Android App to track Epigral share price live.

Conclusion

The Epigral share price forecast for the next 3 years spans Rs 1,260 to Rs 2,050 by 2030 under the scenarios discussed, with a base case near Rs 1,620. Any credible Epigral share price forecast must be updated as facts change, and the path will be decided by earnings delivery, rising domestic demand for chlor-alkali derivatives and specialty chemicals and capacity expansion and the broader market environment. Treat these ranges as a framework for thinking, not a promise of outcomes, and revisit the assumptions as new results come in. Consult a SEBI registered investment advisor before making any investment decision.

What is the Epigral share price forecast for the next 3 years?

Ans. The Epigral share price forecast for the next 3 years is scenario based rather than a single number. By 2030, the illustrative range spans Rs 1,260 in the bear case to Rs 2,050 in the bull case, with a base case near Rs 1,620, depending on earnings delivery and market conditions.

What is the Epigral share price forecast for 2027?

Ans. For 2027, the scenario range works out to Rs 1,120 to Rs 1,310, with a base case around Rs 1,210. This assumes compounding on the current price of Rs 1,052 and is illustrative, not a guaranteed outcome.

What is the Epigral share price forecast for 2028?

Ans. The 2028 scenario range is Rs 1,160 to Rs 1,530, with the base case near Rs 1,340. Actual levels will depend on earnings growth, sector trends and overall market valuations at the time.

What is the current share price of Epigral?

Ans. Epigral currently trades at around Rs 1,052 on the NSE, within a 52 week range of Rs 806 to Rs 2,114. Prices change continuously during market hours, so check live quotes before acting.

Is Epigral a good stock for the long term?

Ans. Epigral has a credible long term story built on rising domestic demand for chlor-alkali derivatives and specialty chemicals and capacity expansion, but it also carries risks since energy intensive manufacturing makes margins sensitive to power costs and caustic soda price cycles. Long term suitability depends on your risk profile and portfolio, so consult a SEBI registered investment advisor before investing.

What is the Epigral share price outlook for 2030?

Ans. The Epigral share price outlook for 2030 spans Rs 1,260 to Rs 2,050 across bear and bull scenarios. Where the stock actually lands will be driven by profit growth, valuation multiples and macro conditions closer to that date.

What are the key risks to the Epigral share price forecast?

Ans. The main risks are execution delays, valuation compression from the current PE of 13.9, sector specific pressures, macro shocks and regulatory changes. Any of these can push the stock below the base case scenario discussed in this article.